Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague

Antimicrob Agents Chemother. 2014 Jun;58(6):3276-84. doi: 10.1128/AAC.02420-14. Epub 2014 Mar 31.

Abstract

It has been previously shown that mice subjected to an aerosol exposure to Yersinia pestis and treated with β-lactam antibiotics after a delay of 42 h died at an accelerated rate compared to controls. It was hypothesized that endotoxin release in antibiotic-treated mice accounted for the accelerated death rate in the mice exposed to aerosol Y. pestis. Imipenem, a β-lactam antibiotic, binds to penicillin binding protein 2 with the highest affinity and produces rounded cells. The binding of imipenem causes cells to lyse quickly and thereby to release less free endotoxin. Two imipenem regimens producing fractions of time that the concentration of free, unbound drug was above the MIC (fT>MIC) of approximately 25% (6/24 h) and 40% (9.5/24 h) were evaluated. In the postexposure prophylaxis study, the 40% and 25% regimens produced 90% and 40% survivorship, respectively. In the 42-h treatment study, both regimens demonstrated a 40 to 50% survivorship at therapy cessation and some deaths thereafter, resulting in a 30% survivorship. As this was an improvement over the results with other β-lactams, a comparison of both endotoxin and cytokine levels in mice treated with imipenem and ceftazidime (a β-lactam previously demonstrated to accelerate death in mice during treatment) was performed and supported the original hypotheses; however, the levels observed in animals treated with ciprofloxacin (included as an unrelated antibiotic that is also bactericidal but should cause little lysis due to a different mode of action) were elevated and significantly (7-fold) higher than those with ceftazidime.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aerosols
  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Ceftazidime / pharmacokinetics
  • Ceftazidime / pharmacology
  • Ceftazidime / therapeutic use
  • Ciprofloxacin / pharmacokinetics
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use
  • Cytokines / metabolism
  • Endotoxins / analysis
  • Female
  • Imipenem / pharmacokinetics
  • Imipenem / pharmacology
  • Imipenem / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Plague / metabolism
  • Plague / microbiology
  • Plague / prevention & control*
  • Survival Analysis
  • Yersinia pestis / drug effects*

Substances

  • Aerosols
  • Anti-Bacterial Agents
  • Cytokines
  • Endotoxins
  • Ciprofloxacin
  • Imipenem
  • Ceftazidime